What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?

Are there specific clinical or social scenarios that would preclude the use of this treatment?

Answer from: at Academic Institution

Poorly controlled Hypertension Active flare of autoimmune disease On immunosuppressant therapies

Answer from: at Academic Institution

Patients with active auto-immune disease or uncontrolled hypertension should give one pause.